Glaxosmithkline Pharmaceuticals Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

GlaxoSmithKline Pharmaceuticals has fixed 30 May 2025 as record date for determining entitlement of members to final dividend for the financial year ended 31st March 2025. The dividend, if approved, shall be paid on or after 30 June 2025.

Powered by Capital Market - Live News

Profit before tax stood at Rs 354.90 crore, up 32.08% from Rs 268.71 crore in the same period last year. Total expenses declined 3.53% YoY to Rs 650.64 crore. Notably, the cost of materials consumed dropped 43.65% YoY to Rs 108.35 crore, while employee benefits expense fell 11.49% to Rs 152.97 crore.

On a full-year basis, the company's net profit jumped 57.19% to Rs 919.06 crore on a 9.28% rise in revenue to Rs 3,723.49 crore in FY25 over FY24.

Bhushan Akshikar, managing director of GlaxoSmithKline Pharmaceuticals, said, ?Our diversified portfolio of general medicines, specialty, and vaccines has shown improved growth due to sustained innovation, enhanced healthcare professional (HCP) engagement, and rapid digital acceleration. This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customers.

Our key brands, including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy, have played a significant role in driving growth throughout the year. Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country.?

The company said it is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer, and Jemperli (Dostarlimab), an immunotherapy for second-line treatment of endometrial cancer.

Meanwhile, the board recommended a final dividend of Rs 42 per equity share for FY25, subject to shareholder approval at the company?s 100th Annual General Meeting.

GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies.

Powered by Capital Market - Live News

Net profit of Glaxosmithkline Pharmaceuticals rose 35.17% to Rs 262.87 crore in the quarter ended March 2025 as against Rs 194.48 crore during the previous quarter ended March 2024. Sales rose 4.79% to Rs 974.37 crore in the quarter ended March 2025 as against Rs 929.80 crore during the previous quarter ended March 2024.

For the full year,net profit rose 57.23% to Rs 927.58 crore in the year ended March 2025 as against Rs 589.96 crore during the previous year ended March 2024. Sales rose 8.56% to Rs 3749.21 crore in the year ended March 2025 as against Rs 3453.71 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

Net profit of Glaxosmithkline Pharmaceuticals rose 34.73% to Rs 260.14 crore in the quarter ended March 2025 as against Rs 193.08 crore during the previous quarter ended March 2024. Sales rose 6.06% to Rs 966.08 crore in the quarter ended March 2025 as against Rs 910.87 crore during the previous quarter ended March 2024.

For the full year,net profit rose 57.19% to Rs 919.06 crore in the year ended March 2025 as against Rs 584.69 crore during the previous year ended March 2024. Sales rose 9.28% to Rs 3723.49 crore in the year ended March 2025 as against Rs 3407.25 crore during the previous year ended March 2024.

Powered by Capital Market - Live News